Research - Page 6 of 718 Posts on Medivizor
Navigation Menu

Research Posts on Medivizor

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Evaluating the effectiveness and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced NSCLC.

Posted by on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of toripalimab (Tuoyi) in combination with chemotherapy as a first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that toripalimab in combination with chemotherapy significantly improved overall survival and survival without cancer...

Read More

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of radium-223 dichloride treatment in real-world patients with metastatic castration-resistant prostate cancer.

Posted by on Apr 30, 2023 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety of radium-223 dichloride (Xofigo) treatment in real-world patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that radium-223 dichloride treatment was well tolerated and reduced pain in real-world patients with mCRPC spread to the bone. Some...

Read More

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Evaluating the risk of cardiovascular side effects in cancer patients treated with PD-1/PD-L1 inhibitors.

Posted by on Apr 30, 2023 in Melanoma | 0 comments

In a nutshell This study evaluated the risk of cardiovascular (CV; heart and blood vessels) side effects in cancer patients treated with PD-1/PD-L1 inhibitors. The data showed that PD-1/PD-L1 inhibitors alone or combined with chemotherapy significantly increased the risk of CV side effects. PD-1/PD-L1 inhibitors combined with chemotherapy significantly...

Read More

Evaluating the effects of split-belt treadmill versus tied-belt treadmill training on gait adaptation in patients with Parkinson’s disease.

Evaluating the effects of split-belt treadmill versus tied-belt treadmill training on gait adaptation in patients with Parkinson’s disease.

Posted by on Apr 30, 2023 in Parkinson's Disease | 0 comments

In a nutshell This study evaluated the effects of split-belt treadmill (SBT) versus tied-belt treadmill (TBT) training on gait adaptation in patients with Parkinson’s disease (PD). The data showed that SBT training significantly improved gait adaptation compared to TBT in these patients.  Some background PD is a disorder in which part of...

Read More

Evaluating the effectiveness and safety of adding isatuximab to lenalidomide, bortezomib, and dexamethasone combination for patients with newly diagnosed transplantation-eligible multiple myeloma.

Evaluating the effectiveness and safety of adding isatuximab to lenalidomide, bortezomib, and dexamethasone combination for patients with newly diagnosed transplantation-eligible multiple myeloma.

Posted by on Apr 30, 2023 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding isatuximab (Sarclisa) to lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (Decadron) combination as induction therapy for patients with newly diagnosed transplantation-eligible multiple myeloma (MM). The data showed that the addition of isatuximab to lenalidomide,...

Read More

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Evaluating the effectiveness and safety of a tumor bed boost after whole breast irradiation following breast-conserving surgery in patients with non-low-risk ductal carcinoma in situ.

Posted by on Apr 23, 2023 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of a tumor bed (where the tumor was present) boost after whole breast irradiation (WBI) following breast-conserving surgery (BCS) in patients with non-low-risk ductal carcinoma in situ (DCIS). The data showed that a tumor bed boost after WBI following BCS reduced local recurrence (return...

Read More

Evaluating the long-term outcomes of catheter-based renal artery denervation in patients with uncontrolled hypertension.

Evaluating the long-term outcomes of catheter-based renal artery denervation in patients with uncontrolled hypertension.

Posted by on Apr 23, 2023 in Hypertension | 0 comments

In a nutshell This study reported the long-term outcomes of catheter-based renal artery denervation (CB-RD) in patients with resistant or uncontrolled hypertension [high blood pressure (BP)]. The data showed that over the long-term CB-RD was safe and had significantly greater reductions in BP and better BP control compared with a sham control in these...

Read More

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Evaluating the effectiveness and safety of asciminib in real-world patients with chronic myeloid leukemia previously treated with ponatinib.

Posted by on Apr 23, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness and safety of asciminib (Scemblix) in real-world patients with chronic myeloid leukemia (CML) previously treated with ponatinib (Iclusig). The data showed that asciminib treatment had promising effectiveness in these patients. Some background CML is a type of cancer that starts in blood-forming...

Read More

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Evaluating the effectiveness of degarelix with or without apalutamide before prostate surgery in patients with high-risk prostate cancer.

Posted by on Apr 23, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of degarelix (Firmagon) with or without apalutamide (Erleada) before radical prostatectomy (RP; prostate surgery) in patients with high-risk prostate cancer (PC). The data showed that degarelix plus apalutamide significantly improved the pathological response in these patients. Some background...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor